Novavax, Inc. filed its quarterly report on Form 10-Q with the SEC on August 6, 2026, covering the three and six months ended June 30, 2026, disclosing a net loss for both periods alongside a widened stockholders' deficit compared to year-end 2025.

Key Highlights

  • Second-quarter net loss: Novavax reported a net loss of $53,387 thousand for the three months ended June 30, 2026, according to the filing.
  • Second-quarter total revenue: Total revenue was $56,698 thousand for Q2 2026, consisting of $18,854 thousand in product sales and $37,844 thousand in licensing, royalties, and other.
  • First-half net loss: For the six months ended June 30, 2026, the company reported a net loss of $62,878 thousand, compared to net income of $625,154 thousand in the same period of 2025.
  • Stockholders' deficit: Total stockholders' deficit stood at $190,707 thousand at June 30, 2026, compared to $127,753 thousand at December 31, 2025, as reported in the balance sheet.
  • Cash and marketable securities: Cash and cash equivalents were $191,458 thousand and marketable securities were $527,882 thousand as of June 30, 2026.
  • Shares outstanding: 164,945,726 shares of common stock were outstanding as of July 31, 2026, as stated on the filing's cover page.

Novavax Financial Results for the Quarter and Six Months Ended June 30, 2026

According to the filing, Novavax, Inc. (Nasdaq: NVAX), a vaccine company headquartered in Gaithersburg, Maryland, recorded total revenue of $56,698 thousand for the three months ended June 30, 2026. This compared to total revenue of $239,240 thousand in the same quarter of 2025, with the prior-year period reflecting $228,516 thousand in licensing, royalties, and other revenue. For Q2 2026, total expenses were $111,604 thousand, resulting in a loss from operations of $54,906 thousand, as disclosed in the consolidated statements of operations.

For the six months ended June 30, 2026, the company reported total revenue of $196,212 thousand, down from $905,895 thousand in the first half of 2025, which the filing attributes in part to $632,402 thousand in product sales and $273,493 thousand in licensing, royalties, and other in that prior-year period. Research and development expenses for the first half of 2026 were $166,165 thousand, and selling, general, and administrative expenses were $55,442 thousand, according to the filing.

The consolidated balance sheet as of June 30, 2026, showed total assets of $955,575 thousand and total liabilities of $1,146,282 thousand. The accumulated deficit reached $4,631,026 thousand at June 30, 2026, compared to $4,568,148 thousand at December 31, 2025. Long-term debt was reported at $291,490 thousand, up from $244,213 thousand at year-end 2025. Deferred revenue, both current and non-current, totaled $443,332 thousand at June 30, 2026, as shown in the balance sheet.

What Was Disclosed

Novavax's 10-Q for the period ended June 30, 2026, disclosed a net loss of $53,387 thousand in Q2 2026 and $62,878 thousand for the first half of 2026, a widened stockholders' deficit of $190,707 thousand, and total revenue of $196,212 thousand for the six-month period, all sourced from the company's unaudited consolidated financial statements.